PDZK1抗动脉粥样硬化的研究进展  

Research progress of PDZK1 in anti-atherosclerosis

作　　者：李婉琳 安换换 孟妍 迟锦玉[1] Li Wan-lin;AN Huan-huan;Meng yan;CHI Jin-yu(Department of Cardiology,the First Affiliated Hospital of Harbin Medical University,Harbin 150001,Heilongjiang,China)

机构地区：[1]哈尔滨医科大学附属第一医院心内科,黑龙江哈尔滨150001

出　　处：《心脏杂志》2023年第5期597-599,603,共4页Chinese Heart Journal

基　　金：国家自然科学基金项目(81800352);黑龙江省博士后启动金项目(LBH-Q18093)。

摘　　要：PDZ结构域蛋白1(PDZK1)是Na+/H+交换调节因子的蛋白质家族成员之一,也是经典的细胞膜支架/适配蛋白。现已明确PDZK1可通过调节脂质代谢和参与巨噬细胞、内皮细胞、血管平滑肌细胞中高密度脂蛋白(HDL)介导的信号转导通路调控动脉粥样硬化的病理生理过程。未来应深入研究PDZK1在动脉粥样硬化中的具体调控机制,为疾病的防治及预后提供新的、更有效的潜在靶点。PDZK1:a member of the protein family of Na+/H+exchange regulators,is considered to be a classic cell membrane scaffold/adapter protein.Nowadays it is clear that PDZK1 can regulate the pathophysiological process of atherosclerosis by participating in lipid metabolism and HDL mediated signal transduction pathway in macrophages,endothelial cells and vascular smooth muscle cells.In the future,we should study the specific regulatory mechanism of PDZK1 in atherosclerosis deeply,so as to provide new and more effective potential targets for disease prevention and prognosis.

关 键 词：PDZK1 HDL 信号转导通路 动脉粥样硬化 

分 类 号：R543.5[医药卫生—心血管疾病]